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Abstract
Background: As emphasized by international recommendations and largely confirmed by clinical experience,
long-acting bronchodilators play a central role in the maintenance treatment of chronic obstructive pulmonary
disease (COPD) due to their proven efficacy in reducing airflow obstruction and improving symptoms.
Main body: There are some important aspects to define with regard to inhalation therapy for COPD, particularly
those concerning the selection criteria and the optimal use of long-acting bronchodilators. First of all, it needs to be
determined in which patients and clinical situations monotherapy with one bronchodilator, such as a long-acting
muscarinic antagonist (LAMA), should be considered adequate, and in which cases the use of combination therapies,
such as the “double bronchodilation” with a LAMA and a long-acting β2-agonist (LABA), should be preferred. Another
critical issue concerns the effect of the frequency of daily administration of inhaled agents on the control of symptoms
during the 24 h. COPD symptoms are known to exhibit considerable circadian variability with worsening in the early
morning, and a significant proportion of patients have disease-related sleep disorders which can adversely affect their
quality of life. The worsening of symptoms in the early morning may be due, at least in part, to a reduction in airway
caliber caused by an increased “cholinergic tone” at night. As such, the coverage of nighttime and early morning
symptoms is a reasonable therapeutic goal, which can be achieved by many patients using LAMAs such as aclidinium
bromide twice daily (BID). Therapeutic adherence is known to be a multifactorial phenomenon that is frequently
affected by other aspects than dosing frequency, including the technical features and ease of use of the inhalers.
To this end, it should be mentioned that certain new-generation inhalers such as Genuair® have been associated
in clinical trials with higher patient preference.
Conclusion: In this work, in addition to presenting an overview of the main evidence on the efficacy of COPD
treatment with the LAMA aclidinium bromide BID, we suggest some selection criteria for the monotherapy with
one long-acting bronchodilator or the combination therapy with LAMA and LABA in COPD patients, with particular
reference to specific clinical scenarios.
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Background
Chronic obstructive pulmonary disease (COPD) is a
common, preventable and treatable disease characterized
by persistent, usually progressive airflow limitation, caused
by both small airway disease (obstructive bronchiolitis)
and parenchymal destruction (emphysema), the relative
contributions of which vary from person to person.
Characteristic symptoms of this chronic respiratory
disease include dyspnea, cough and sputum production.
Usually, a person suffering from COPD will decide to
consult a physician because of the negative impact of
their symptoms on their daily living activities, but also
because of the persistence of symptoms or the occur-
rence of exacerbations.
COPD, a major cause of morbidity and mortality
worldwide, involves a significant and increasing eco-
nomic and social burden. The disability adjusted life
years (DALYs) for a specific disease are calculated as the
sum of the years of life lost due to premature mortality
and the years of life lived with disability, adjusted for the
severity of the disease. In 1990, COPD was the twelfth
leading cause of lost DALYs worldwide, accounting for
2.1% of the total. It is predicted that by 2030 this
disease will be the seventh leading cause of lost DALYs
globally [1].
Main text
Direct and indirect costs of COPD
COPD involves a significant economic burden. In the
European Union, the total direct costs of respiratory
disease are estimated to be about 6% of the total health
budget, with COPD alone accounting for 56% (38.6
billion Euros) of this budget. In the United States, the
costs of COPD are estimated to be $29.5 billion for
direct costs and $20.4 billion for indirect costs. Exacer-
bations account for the greatest proportion of health
care costs related to COPD. Therefore, the close cor-
relation between disease severity and health care costs
is not surprising, with the distribution of health ex-
penditure changing with the progression of the disease.
Any estimate of the direct medical costs of home care
does not reflect the true home care costs for society, as it
does not take into account the economic value of care
provided by family members to COPD patients [2].
Pathophysiology of COPD symptoms - circadian
variability
The traditional definition of COPD as a slowly progres-
sive disease in which the deterioration of lung function
is associated with an increase in symptoms, has been
questioned by scientific evidence accumulated in recent
years. Several studies have in fact demonstrated that the
extent and perception of COPD symptoms are not as
stable as previously believed, but show a variability that
is not only seasonal, but also weekly and even daily, with
symptoms often worsening at night and in the early
morning [3, 4].
Circadian variability of COPD symptoms was also con-
firmed by a survey conducted on a sample of 803 COPD
patients, which showed an increase in clinical manifesta-
tions especially in the early morning (P <0.001 versus
“midday”, “afternoon”, “evening”, “night” and “difficult to
say” for all COPD patients; P <0.001 versus “midday” for
patient with severe COPD symptoms) and at night [5].
There is also evidence that the main symptoms of COPD
show different temporal trends during the 24 h; in
particular, it has been found that dyspnea, sputum pro-
duction and cough tend to worsen especially in the
morning, while wheezing shows a peak of variability at
night, and tightness in the chest displays a highly vari-
able trend during the 24 h [6].
From the pathophysiological viewpoint, the circadian
variability of COPD symptoms, and especially the in-
crease in symptoms at night/early morning, may be due,
at least in part, to circadian modulation of the airway
caliber by the cholinergic system. Like many other bio-
logical variables, airway caliber shows a certain variability
during the 24 h, reaching peak values around midday, with
lower values at night and in the early morning. A central
cholinergic mechanism is believed to be responsible for
modulating the variability in airway caliber (“cholinergic
tone”). The worsening of symptoms at night or in the early
morning, which is found in many patients with COPD,
may be at least partially attributed to a pathological in-
crease in this circadian variation [7].
Nighttime/early morning symptoms and decreased
performance/QoL in COPD patients
It is currently believed that improvements in “patient-
centered” outcomes, including subjective symptoms, can
reflect more accurately the effectiveness of pharmaco-
logical treatment of COPD compared with changes in
forced expiratory volume in 1 s (FEV1), which are often
transient and do not adequately reflect the real impact
of treatment on the quality of life of patients.
A weak correlation between symptom perception by pa-
tients and FEV1 values is, in fact, often found in COPD;
accordingly, subjective indicators relating to quality of life
(QoL) and health-related quality of life (HR-QoL) are now
considered as part of the therapeutic evaluation [8]. An
example of such “patient-centered” outcomes is given by
the circadian variability of COPD symptoms, which has
been shown to adversely affect the performance of normal
daily activities and to have a substantial negative impact
on the quality of life [4].
Nighttime symptoms are particularly troublesome for pa-
tients with COPD as these symptoms are often associated
with poor quality of sleep [9, 10]. However, the presence of
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nocturnal symptoms in a patient with chronic airway
disease should prompt health care professionals to make a
differential diagnosis between COPD and asthma, as well
as to exclude or confirm the presence of (concomitant)
heart failure. To this end, a survey conducted by primary
care physicians and respiratory specialists from several
European countries (France, Germany, Italy, Spain and the
UK) on a retrospective cohort of 2807 patients with COPD,
showed that the majority of enrolled subjects (78%) re-
ported the presence of sleep disorders (i.e., difficulty in
falling asleep, frequent nocturnal awakenings, difficulty in
maintaining sleep), with nighttime symptoms associated
with greater disease severity i.e., more daytime symptoms
and more frequent exacerbations) [11, 12].
Similar to effects of nighttime symptoms, various studies
have found that morning symptoms are also a significant
burden to patients with COPD. Moreover, early morning
has been reported as the worst time of a day by many
COPD patients, especially among those with severe
disease; moreover, early morning COPD symptoms limit
patients’ ability to perform their normal activities [13–15].
The recent observational ASSESS study, which in-
cluded more than 700 patients with COPD, performed
in a real-life context, has confirmed the significant
prevalence of nighttime symptoms (52%), which tend to
be associated both with greater symptom severity, as
assessed by the COPD Assessment Test (CAT), and
higher prevalence of anxiety and depression, as assessed
by the Hospital Anxiety and Depression Scale (HADS)
[16]. In the clinical practice, however, the circadian vari-
ability is often not adequately taken into consideration
in the therapeutic approach; for example, a real-life clini-
cal study showed that drug treatment was not changed
in more than half of patients surveyed, even though a
significant worsening of symptoms over 24 h was noted.
On the other hand, paying attention to the progression
of symptoms over the course of 24 h is also important
from the therapeutic point of view, as this can help to
identify different types of patients, as well as to establish
the most appropriate therapeutic strategy to mitigate the
impact of symptoms on HR-QoL.
For these reasons, patients with COPD should be
specifically questioned about daytime and nighttime
symptoms and their impact on quality of life. The imple-
mentation of appropriate strategies for the optimal
control of symptoms is also recommended, with particu-
lar regard to the time of maximum symptom intensity
(e.g., nighttime, early morning) [4].
Inappropriate overuse of LABA + ICS and LABA + LAMA +
ICS combinations in COPD patients that belong to A or
B-GOLD groups
Although the Global strategy for the diagnosis, manage-
ment, and prevention of COPD (GOLD) recommendations
indicate that monotherapy with a long-acting bronchodi-
lators is the treatment of choice in group A and B pa-
tients, an inappropriate “overuse” of combinations with
inhaled corticosteroids (ICS) and bronchodilators is often
observed in the clinical practice. This inappropriate over-
use of ICS-containing regimens is often in conflict with
the need for a careful real-world assessment of the risk-
benefit ratio of COPD treatments [17].
To this end, it is worth mentioning the results of a re-
cent observational study conducted in the UK on a data-
set of primary-care patients with COPD, which showed
that the prescription pathways leading to a real-world
use of “triple therapy” (TT) with LABA + LAMA + ICS
differ considerably from those recommended by inter-
national recommendations [18]. In particular, this study
found that ICS-containing TT regimens were also fre-
quently prescribed to patients at low-risk of exacerbations
and/or without concomitant asthma, who, according to
current guidelines, do not need such treatments. The
“progression” to TT occurred in 25% of cases within the
first year of treatment and in 40% within the first two
years [18] (Fig. 1).
The overuse of ICS-containing regimens can lead to
several problems from the point of view of public health,
with increased costs not justified by any superior
efficacy, and from the viewpoint of safety, since chronic
exposure to ICS can carry the risk of several side effects
(including pneumonia, osteoporosis, etc) [2, 18]. Another
fact emerging from the above UK survey is the low pre-
scribing rates of long-acting bronchodilators as first-line
therapy, which, together with the evidence of inappropri-
ate prescribing of TT, emphasizes the need to provide
better information and training for health care providers,
in order to improve real-world implementation of COPD
recommended management programs [18–22].
Fig. 1 Cumulative proportion of COPD patients receiving “triple therapy”
(TT) with LABA + LABA + ICS by GOLD (Global initiative for chronic
Obstructive Lung Disease) group, based on a UK primary-care database
(2002–2010). Note: P = 0.065 (chi-square test). Elaboration of textual data
from [16]
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Rationale of bronchodilator monotherapy in symptomatic
COPD patients
The administration of long-acting bronchodilators, such
as LAMA or LABA, plays a central role in the control of
symptomatic COPD [16]. There is also evidence showing
that bronchodilators may have a significant role in the
control of circadian variability of symptoms and in im-
proving the quality of life of patients with COPD [4].
An interesting therapeutic “target” in this context is
the increased “cholinergic tone” in patients with COPD;
this phenomenon, due to various mechanisms not yet
fully elucidated [23], seems to be particularly relevant at
night and may contribute to the frequent occurrence of
early morning symptoms in patients with COPD. The
therapeutic role of LAMAs is therefore of great interest
in view of these pathophysiological aspects, which are
particularly important in patients with nocturnal symp-
toms and/or significant circadian variability of symptoms.
The effectiveness of these drugs in reducing airway
obstruction and lung hyperinflation, leading to an im-
provement in a variety of “patient-centered” outcomes, is
well-documented [24]. In particular, due to their specific
modulating action on cholinergic tone, LAMAs can
effectively control the symptoms for 24 h, especially when
administered as a twice-daily regimen, which provides a
better coverage of the “critical” nighttime period, as in the
case of aclidinium bromide [25].
Role of the LAMA aclidinium bromide in COPD treatment
Aclidinium bromide is a potent and selective LAMA,
characterized by rapid onset and long duration of action;
it also has a good cardiovascular safety profile, which
may be attributed to its reduced residence time at M2
receptors and its rapid hydrolysis in plasma [26].
In experimental models, aclidinium showed a faster
onset of action than the LAMA tiotropium [26]. Fur-
thermore, in a study that assessed the onset of action of
LAMAs (aclidinium, glycopyrronium and tiotropium, all
administered at the approved clinical doses) in moderate-
to-severe COPD patients, bronchodilation induced by
aclidinium and glycopyrronium was faster than that
induced by tiotropium, without significant difference
between aclidinium and glycopirronium [27].
Aclidinium bromide also exhibits potential anti-
inflammatory and anti-airway remodeling effects, as
shown by studies of experimental animal models, which
can be an “added value” in the therapeutic management
of COPD [23].
For example, there is some evidence that aclidinium
bromide could modulate the non-neuronal cholinergic
system, a recently identified regulatory pathway in pul-
monary inflammation and remodeling [28]. Dysfunction
of the non-neuronal cholinergic system seems to be in-
volved in the pathophysiology of COPD and to some
extent in resistance to corticosteroid therapy; in fact,
non-neuronal cholinergic system is over-expressed in
corticosteroid-insensitive neutrophils from COPD patients,
as evidenced by increases in the expression of muscarinic
receptors (M2, M4 and M5), vesicular acetylcholine trans-
porter (VAChT) and choline acetyltransferase (ChAT).
In a recent in vitro study, aclidinium bromide demon-
strated anti-inflammatory effects on neutrophils from
COPD patients, reversing their resistance to corticoste-
roids; in fact, the addition of aclidinium bromide increased
the impaired anti-inflammatory properties of a cortico-
steroid (fluticasone propionate) by a mechanism involving
the inhibition of Glucocorticoid Receptor Alpha (GRα)
phosphorylation at Ser-226, the enhancement of cor-
ticosteroid- mediated Glucocorticoid Response Element
(GRE) activation and the expression of corticosteroid-
dependent anti-inflammatory genes, i.e. Mitogen-activated
Protein Kinase Phosphatase 1 (MKP1), Cysteine-RIch
Secretory Protein LCCL Domain-containing 2 (CRISPLD2)
and (GILZ) [28]. Among aclidinium bromide therapeutic
properties, it seems to be interesting as well its favourable
effect on hyperinflation and airflow limitation, that plays a
very important pathophysiological role in inducing dyspnea
and reducing quality of life (QoL) in COPD patients; in this
regard, it has been recently demonstrated that aclidinium
promotes a rapid and relevant desufflation and improves
lung ventilation inhomogeneity, even in severe/very severe
COPD patients [29].
The clinical efficacy of twice-daily (BID) aclidinium
bromide is clearly demonstrated by the results of a large
number of both placebo-controlled and active-comparator
trials [30–36].
With regard to overall efficacy in the treatment of
COPD, a Cochrane Review of 12 double-blind randomized
controlled trials, lasting 4 to 52 weeks, on a total of 9547
patients with stable COPD, demonstrated that aclidinium
bromide BID significantly improved quality of life by
lowering the St. George’s Respiratory Questionnaire
(SGRQ) total score by 2.34 units compared to placebo
(95% confidence interval [CI] 3.18 to 1.51), significantly
increased FEV1 with a mean difference of 0.09 L compared
to placebo (95% CI 0.08 to 0.10), and reduced the number
of patients with exacerbations requiring hospitalization
(OR 0.64; 95% CI 0.46 to 0.88) [31].
Aclidinium bromide BID can provide sustained bron-
chodilation over 24 h, which is associated with signifi-
cant improvement in FEV1 area under the curve (AUC),
especially at night and early morning [32].
As regards the potential to effectively control the cir-
cadian variability of COPD symptoms, particularly inter-
esting are the results of a multicenter, randomized,
double-blind trial comparing aclidinium bromide 400 μg
BID with placebo and tiotropium 18 μg OD in 795 patients
with moderate-to-severe COPD, treated in a real-life
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context. During the period of treatment with aclidinium
bromide 400 μg BID, the proportions of patients with
nighttime and morning symptoms and limitation in
morning activities were significantly reduced from base-
line (p <0.0001 for all tests) [33].
The efficacy of aclidinium bromide in terms of
symptom control over the entire 24-h period was also
confirmed in a double-blind, randomized trial comparing
aclidinium 400 μg BID with tiotropium 18 μg once-daily
(OD) or placebo for six weeks on 414 patients with
moderate-to-severe COPD [30]. At the end of the treat-
ment period, symptom scores, assessed using specific
questionnaires, were significantly reduced from baseline
with both aclidinium (p <0.0001) and tiotropium (p <0.05)
compared to placebo. It should be noted, however, that
only aclidinium, but not tiotropium, resulted in significant
improvements compared with placebo with regard to indi-
vidual morning symptoms (phlegm, shortness of breath,
wheezing, and cough) and severity of nocturnal symp-
toms; moreover, only aclidinium significantly reduced
the limitation of activity caused by symptoms, with a
significant difference compared to tiotropium (p <0.05).
The results of this study, in terms of greater potential
of aclidinium to control the symptomatic manifesta-
tions of COPD, might be related to differences in dosing
frequency between aclidinium and tiotropium; in particu-
lar, the second evening dose of aclidinium, administered
in the evening, which is closer to the time of maximum
intensity of respiratory symptoms, may be beneficial in
improving nighttime and early morning symptoms.
In COPD patients, reducing the severity of respiratory
symptoms is a very important treatment goal, as they are
associated with poor health outcomes, reduced health
status and increased exacerbation risk.
In this regard, a recent post-hoc analysis of pooled
data from the aclidinium 400 μg BID and placebo arms of
two 24-week, double-blind, randomized studies, evaluating
aclidinium monotherapy or combination therapy with
aclidinium plus LABA formoterol, assessed the effect of
aclidinium bromide on respiratory symptoms in moderate-
to-severe COPD patients. According to the conclusions of
this paper, aclidinium 400 μg BID significantly improved
COPD respiratory symptoms, as assessed by the Evaluating
Respiratory Symptoms in COPD (ERS-COPD) scale, irres-
pective of the patients’ level of symptoms at baseline; in
fact, net treatment benefit by aclidinium compared to pla-
cebo was found to be similar in patients with low or high
levels of COPD symptoms [37].
Aclidinium bromide has confirmed its efficacy also in
the long term, as demonstrated by the results of a 52-
week double-blind, parallel group trial, performed on
605 patients with moderate-to-severe COPD. Treatment
with aclidinium bromide BID resulted in clinically import-
ant improvements (reduction ≥4 points from baseline) in
symptom scores and in quality of life as assessed by SGRQ
score at all study visits (performed at weeks 1, 12, 24, 36,
48 and 52) [34].
With regard to the tolerability profile, it should be
noted that receptor selectivity and rapid plasma hydroly-
sis of aclidinium to inactive metabolites can explain the
low incidence of systemic adverse events observed in
clinical trials; such events, including anticholinergic side
effects, were also generally mild [35, 36] (Table 1).
As a result of the large systemic and pre-systemic hy-
drolysis, the absolute bioavailability of aclidinium is very
low (<5%), and significantly lower than that of tiotro-
pium and glycopyrronium (45% and 19%, respectively)
[38–40]. Cardiovascular adverse events have been re-
ported with similar frequency in patients treated with acli-
dinium bromide and in those assigned to placebo group,
supporting the safety of aclidinium in patients with COPD
and concomitant cardiovascular disease [41, 42].
Adherence to inhaled therapies: what is more important,
frequency of administration or patient preference?
Some authors have advanced the hypothesis that, in
terms of patient’s adherence to medical treatment,
twice-daily dosing of inhaled medications is less favor-
able than once-daily dosing, but the available evidence
Table 1 Number (%) of patients with potential anticholinergic
adverse events by system organ class and preferred term
(safety population) (Table 3 of [36], reproduced by permission)
System organ class/
preferred term
Placebo
(n = 182)
Aclidinium 200 μg
(n = 183)
Aclidinium 400 μg
(n = 177)
Cardiac disorders
Tachycardia 0 0 1 (0.6)
Arrhythmia 1 (0.5) 0 0
Bradycardia 2 (1.1) 0 0
Palpitations 0 2 (1.1) 0
Increased heart ratea 0 2 (1.1) 0
Eye disorders
Transient blindness 0 1 (0.5) 0
Reduced visual acuity 0 1 (0.5) 0
Gastrointestinal disorders
Constipation 3 (1.6) 1 (0.5) 0
Dry mouth 1 (0.5) 2 (1.1) 3 (1.7)
Infections and infestation disorders
Urinary tract infection 0 3 (1.6) 1 (0.6)
Nervous system disorders
Optic neuritis 0 0 1 (0.6)
Renal and urinary disorders
Urinary retention 0 0 1 (0.6)
Urinary incontinence 1 (0.5) 0 0
aInvestigations is the system organ class for this preferred term
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in literature does not support this hypothesis. For in-
stance, an observational study has demonstrated that the
high frequency of drug administration may be a major
problem for therapeutic adherence only in the case of
three- and four-times-daily regimens, while there are no
particularly significant differences between twice- and
once-daily regimens [31].
On this subject there are interesting data from a recent
study conducted in Spain on more than 16,000 patients
treated with inhaled LAMAs (aclidinium, tiotropium, or
glycopyrronium), which evaluated the degree of adherence
to two different dosing regimens (once- or twice-daily).
This study showed that adherence to treatment with
LAMAs was generally very high, irrespective of the
molecule or inhalation device used; in particular, there
was no evidence of lower adherence to LAMAs with
BID dosing compared with OD dosing [43].
In this regard, an intriguing hypothesis, which needs
to be verified in future studies, is that the better control
of symptoms (especially of nighttime and early-morning
symptoms) associated with BID dosing may be a signifi-
cant factor for improving treatment adherence to this
dosing regimen.
It should also be remembered that therapeutic adherence
is a multifactorial process that can be affected by a number
of factors different from dosing frequency, including:
perceived efficacy of treatment, side effects, number of
concomitant medications, as well as patient’s satisfaction
with, or preference for, the inhaler device [31].
With regard to the latter, it should be emphasized that,
in order to achieve adequate adherence and, thus, the
maximum benefit from treatment, it is important that
the inhalation device is used correctly. Since an inad-
equate inhaler technique may compromise treatment
efficacy, it is desirable to have devices that are easy to
use, with a few simple “steps” for dosing, and with feed-
back mechanisms to confirm successful inhalation of the
dose. An example of this kind of device is Genuair®, a
multidose, breath-actuated dry powder inhaler (DPI), de-
signed to deliver aclidinium bromide. Genuair® incorpo-
rates a number of technological features that enhance its
performance and safety of use, including the patented
“cyclone” technology to improve deaggregation of aero-
sol particles, thus achieving high drug deposition in the
lungs, as well as visual and acoustic feedback mecha-
nisms that make the device simple and easy-to-use for
the patient [44].
Ease of use, efficiency, and low probability of critical er-
rors with Genuair® are clinically reflected in an increased
patient preference for this inhaler compared to other fre-
quently used devices. To this end, in a recent Italian study
investigating the “usability” of this device in a representa-
tive sample of the elderly population (256 individuals with
COPD, and 89 with hand arthritis/arthrosis), Genuair®
was considered a well-accepted, easy-to-use device by the
great majority of patients studied; moreover, the mean
time to learn and perform the inhalation correctly was
only 1’38”, and more than 70% of patients took less than 2
min to perform this task [45] (Fig. 2).
Aclidinium/formoterol: rationale of combination for
clinical use in COPD patients
The long-acting bronchodilators, LAMA and LABA,
play an important role in the treatment of COPD, as em-
phasized by international recommendations [2, 46, 47].
The combined use of bronchodilators belonging to dif-
ferent drug classes, acting on different receptor systems,
can improve lung function and symptoms, which is par-
ticularly beneficial in patients with moderate-to-severe
COPD [41].
The rationale of the “double bronchodilation” with
LAMA and LABA lies in the fact that the relaxation of
airway smooth muscle (and the resulting bronchodilation)
can be achieved by two main mechanisms:
– inhibition of acetylcholine signaling, mediated
by muscarinic M3 receptors, on airway smooth
muscle with LAMA;
– stimulation of β2-adrenergic receptors with LABA.
The simultaneous pharmacological targeting of these
two mechanisms of bronchodilation can maximize the
bronchodilator response, without the need to increase
the dose of each component of the combination and
thereby reduces the risk of adverse events [48–50].
Fixed-dose combinations (FDCs) of LAMA and LABA
offer the potential of good convenience and compliance.
Among the different LAMA/LABA FDCs, the combina-
tions involving twice-daily dosing, such as the LAMA
aclidinium + LABA formoterol, may be able to better
tailor drug therapy to the individual needs of patients,
including the control of early-morning symptoms, which
are particularly intense and/or frequent in patients with
moderate-to-severe COPD [51].
This was confirmed by a pooled analysis of two 24-
week, double-blind, placebo-controlled, randomized phase
III trials evaluating the efficacy of the FDC aclidinium/
formoterol on 3394 patients with moderate-to-severe
COPD. This analysis showed that the FDC aclidinium/
formoterol was able to improve early morning symp-
toms and to reduce the limitation of early-morning ac-
tivities significantly more (p <0.05) than placebo and
monotherapy with LAMA or LABA [42].
The correct use of bronchodilators in COPD, “when, and
to whom”: therapeutic suggestions
The current availability of a number of active agents and
a variety of drug classes for the treatment of COPD
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makes it often difficult for the physician to select the op-
timal treatment. In our view, the selection of the most
appropriate treatment should take into consideration the
extent of the “disease impact” in a given patient, including
the severity of spirometric obstruction, the symptom bur-
den, the frequency of exacerbations and disease control
[48]. Although LAMA monotherapy may be adequate to
control the disease in certain groups of patients with
COPD, combined therapy with LAMA and LABA, in
combination with an ICS if needed, is often necessary
for specific clinical situations or certain levels of disease
severity.
What is nowadays the therapeutic role in COPD patients
of LAMA used in monotherapy and/or in combination
with other classes of inhaled drugs, such as LABA or ICS?
We advance some therapeutic suggestions, taking also into
account results of the recent FLAME trial and the post-
hoc analysis of the WISDOM trial [51, 52] [(Fig. 3)]:
– COPD patients with ≤ 1 exacerbation/year and
baseline FEV1 ≥ 50% predicted, first-line treatment
with LAMA or LABA; baseline FEV1 < 50% and/or
severe symptoms of dyspnea, first line treatment
LAMA/LABA.
– COPD patients with ≥ 2 exacerbation/year and
low eosinophils blood count [<300/μl], first-line
treatment with LAMA/LABA; high blood
eosinophil count [≥300/μl], first line treatment
with LABA/ICS or LAMA/LABA/ICS; despite
a high eosinophil count, LAMA/LABA can be
considered first line treatment in absence of
allergic or asthma history.
In case of lack of control a step-up therapy should be
considered.
In any case it should be taken into account that the
literature evidence suggests that in patients with mild
A
B
Fig. 2 Assessment of ease of use of the device (Panel a) and mean time to learn the inhaler technique and to perform a correct inhalation (Panel b),
as reported by a recent Italian study which evaluated the usability of the Genuair® device in a representative sample of the elderly population with
COPD/hand arthritis/arthrosis. Elaboration of textual data from [45]
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airflow obstruction according to the GOLD spirometric
classification and relatively moderate symptoms, LAMA
monotherapy (for example, with aclidinium bromide;
other LAMA commercially available are glycopyrronium
bromide, tiotropium and umeclidinium) is often sufficient
to provide adequate symptom control. In the same type of
patients, but with more significant symptoms, the use of
“double bronchodilation” with LAMA/LABA FDC (such
as aclidinium + formoterol; other LAMA/LABA FDC
commercially available are indacaterol/glycopyrronium,
olodaterol/tiotropium, vilanterol/umeclidinium) can be
considered. This LAMA/LABA is also preferred in pa-
tients with moderate-to-severe “disease impact”, including
patients with moderate-to-severe airflow limitation and
significant symptoms; patients with moderate-to-severe
disease, who remain symptomatic despite monotherapy;
patients with moderate-to-severe symptoms, but without
frequent exacerbations. The use of a LAMA can be also
considered as add-on therapy to LABA or ICS/LABA in
case of very severe “disease impact”, e.g., in patients with
severe spirometric obstruction suffering from frequent ex-
acerbations. In these patients, with high eosinophil count
but without history of allergy and asthma, a LAMA/LABA
combination can be proposed as first choice.
Conclusion
Bronchodilator therapy with LAMA, as monotherapy or
in combination with LABA, is one cornerstone of COPD
treatment. Given the circadian variability of symptoms
in patients with COPD, due at least in part to the typical
increased “cholinergic tone” in these subjects, the cover-
age of nighttime and early-morning symptoms should be
considered a reasonable therapeutic target, which can
be achieved by using an appropriate treatment (e.g. a
LAMA such as aclidinium bromide, administered twice
daily). Therapeutic adherence is often good in patients
treated with twice-daily LAMAs, especially if they use a
simple and easy-to-use inhalation device. The selection
of LAMA monotherapy, combination therapy with
LAMA + LABA, or add-on therapy with LAMA to
LABA/ICS, should be individualized based on a com-
prehensive evaluation of the patient with COPD, taking
into account the degree of airway obstruction, the
symptom burden, eosinophil count, history of allergy and
asthma and the frequency and type of exacerbations.
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